Skip to content

Zero Heat Flux Temp Monitor on Discharge Hypothermia Among Trauma Patients (RUZIT Trial)

The Relationship Between the Use of a Continuous a Zero-heat Flux Temperature Monitor on Initial Discharge Hypothermia Rate Among Severely Injured Trauma Patients: a Randomized Controlled Trial. (RUZIT Trial)

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03313258
Acronym
RUZIT
Enrollment
0
Registered
2017-10-18
Start date
2018-07-01
Completion date
2019-05-31
Last updated
2020-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypothermia, Temperature Change, Body, Trauma

Brief summary

Hypothermia amongst trauma patients is a persistent problem that increases the relative risk of transfusion as well as morbidity and mortality. The investigators propose to conduct a single-centered randomized controlled trial to determine if the use of a zero-heat flux (ZHF) temperature monitor can reduce the incidence of hypothermia amongst trauma patients discharged from the trauma bay (TB). All eligible trauma patients will be randomized to either a standard of care group or an active temperature monitoring group. In the active temperature monitoring group, a ZHF monitor will be placed on respective trauma patients to continuously record their temperatures after they enter the TB at a large tertiary trauma centre, Sunnybrook Health Sciences Centre (SHSC), in Toronto, ON. The investigators will determine if early continuous temperature monitoring can reduce the incidence of hypothermia upon discharge from the TB. Should early monitoring of severely injured trauma patients within the hospital improves discharge temperature, the foundation for two additional research studies will be laid. Firstly, the investigators will enter a vanguard phase of this trial and assess if early warming patients can improve morbidity and mortality in this patient population utilizing a multi-centered randomized controlled trial design. This will be further extended to test whether early monitoring can be applied in a pre-hospital setting (i.e. within ambulances and transport vehicles) to improve admission temperatures in the TB.

Interventions

ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.

DEVICEActive Warming Group

ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.

Sponsors

Dr. Asim Alam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \>18 years of age * Severely injured trauma patients with a Revised Trauma Score (RTS) ≤ 11 brought into the SHSC TB.

Exclusion criteria

* Patients with blast injuries to the face or severe facial trauma will be excluded. * Major burn patients - as they follow a separate care pathway at SHSC

Design outcomes

Primary

MeasureTime frameDescription
Hypothermic (<36°C) upon discharge from the trauma bayDuration of their stay in the trauma bay or up to 4 hours in the trauma bay (whichever comes first)Proportion of patients who are hypothermic (\<36°C) upon discharge from the trauma bay.

Secondary

MeasureTime frameDescription
Warming initiativesDuration of their stay in the trauma bay or up to 4 hours in the trauma bay (whichever comes first)Total number of warming initiatives implemented by trauma care team
Transfused productsDuration of their stay in the trauma bay or up to 4 hours in the trauma bay (whichever comes first)Number of transfused blood products
Length of stayTime of admission to discharge or up to 1 year after admission (whichever comes first)Number of days patient stayed in hospital
30 day mortalityTime of admission to discharge or up to 30 days after admission (whichever comes first)Alive or deceased at 30 day

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026